Why Oncology Sponsors Choose Atreo RTSM

When running complex clinical trials, choosing the right RTSM platform can mean the difference between a seamless study and costly operational delays.

In early-phase oncology trials, study designs are inherently dynamic. Sponsors regularly deal with dose-finding phases, cohort expansions, and multi-indication protocols that merge Phase I and Phase II into a single workflow. Managing these shifts requires an exceptionally agile solution for randomization and trial supply management.

The Critical Need for Flexibility in Oncology RTSM

Oncology protocols change fast because they have to follow the science. Traditional IRT and RTSM systems rely on heavy custom coding, meaning a single mid-study change can take weeks to implement and validate. Atreo eliminates this bottleneck by prioritizing configuration over customization.

By leveraging a modern, flexible product architecture, Atreo allows clinical trial sponsors to manage complex workflows efficiently, including:

• Real-time cohort management and rapid dynamic scaling
• Complex drug supply capabilities for multi-drug combination therapies
• Sourcing and tracking investigational products across multiple countries

Supporting Mid-Study Changes Without Delay

Mid-study modifications shouldn't stall your clinical trial timeline. Because Atreo is built on an adaptable engine, adjustments can be made via system configuration rather than a complete recoding effort. This empowers oncology teams to react to incoming clinical data instantly, adjusting dose cohorts or expanding into new tumor types without breaking momentum.

Ready to see how an agile platform can transform your next protocol? Explore our modern RTSM solutions to learn more about Atreo's clinical design capabilities.